EFPIA says IMI is sign of EU "moving in the right direction"
The European Federation of Pharmaceutical Industries and Associations is preparing to appoint its share of members to the governance board of the new Innovative Medicines Initiative, a joint venture with the European Commission (Marketletter December 24, 2007). Brian Ager, the EFPIA's director general, spoke to the Marketletter about the significance of the project and how it fits with the European Union's push for technological excellence under the Lisbon Agenda.
The IMI is a strategic alliance to accelerate the discovery and development of innovative drugs. According to the industry group, it is the first pan-European public-private partnership of its kind in the health care sector. The Initiative's budget is 2.0 billion euros ($2.94 billion) over seven years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze